MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora™ Cream for Treatment of Plaque Psoriasis
POSTED: November 20, 2019
Copenhagen, November 20th, 2019 – MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions, today announced that the U.S. Food and Drug ...
READ FULL ARTICLE >
MC2 Therapeutics Announces Submission of New Drug Application to US FDA for Wynzora™ Cream (Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%) for Treatment of Plaque Psoriasis
POSTED: September 24, 2019
Copenhagen, September 24th, 2019 – MC2 Therapeutics, a late clinical-stage pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions, today announced that it has submitted a ...
READ FULL ARTICLE >
MC2 Therapeutics A/S Completes Enrollment of EU Phase 3 Head-to-Head Study in Patients with Plaque Psoriasis Treated with MC2-01 PADTM Cream
POSTED: August 7, 2019
- Topline data are expected in Q4 2019
Copenhagen, August 7th, 2019 – MC2 Therapeutics A/S, a late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the ...
READ FULL ARTICLE >
MC2 Therapeutics A/S appoints Samia Kappe as Executive Vice President Sales & Marketing Europe
POSTED: April 4, 2019
Copenhagen, April 4th, 2019 – MC2 Therapeutics A/S, a late clinical-stage company focused on topical therapies for chronic inflammatory conditions, today announced the appointment of Samia Kappe as Executive Vice ...
READ FULL ARTICLE >
MC2 Therapeutics A/S announces first patient dosed in EU Phase 3 trial in psoriasis vulgaris
POSTED: January 6, 2019
- First patient dosed in Phase 3 trial assessing the safety and efficacy of MC2-01 Cream in EU
- Topline results are expected in Q3 2019
Copenhagen, January 6th, 2019 – MC2 Therapeutics A/S, ...
READ FULL ARTICLE >
